Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase I/II trial

Baek, Seung-Moon; Kim, Yong‐Man; Kim, Sung‐Bae; Kim, Choung‐Soo; Kwon, Sun Il; Kim, Hyunsoo; Lee, Hyunah

doi:10.1038/cmi.2014.40

Cited by 56 publications

(51 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1) involved autologous DCs exposed to autologous tumor-derived RNA, 196 tumor-cell lysates, [197][198][199][200][201][202][203] autologous tumor stem cell lysates, 204 self-renewing and proliferating autologous tumor cells, 205 allogeneic cancer cell line lysates, [206][207][208] TAAs or TAA-derived peptides [209][210][211][212][213][214][215][216][217][218] or a combination thereof. 219 Most clinical studies based on the latter approach preferred melanoma-associated differentiation antigens including premelanosome protein (PMEL; also known as gp100), antigens belonging to the melanoma antigen gene (MAGE) family, tyrosinase (TYR) and Melan-A (MLANA; also known as MART1) (Fig.…”

Section: Completed Clinical Trialsmentioning

confidence: 99%

“…218,219 Most of these publications documented DC-based vaccines to elicit immune responses (generally in combination with standard-of-care therapies) achieving disease stabilization in most cases and partial or complete responses at a comparatively lower frequency. In several instances, DC-based vaccines have been administered in combination with conventional immunostimulatory agents including cytokines (e.g., IL-2, colony stimulating factor 2 (CSF2; also known as GM-CSF), IFN-a2B, IFNg or IFNb), 199,205,221,224,227 the tetanus toxoid, 185 or TLR agonists. 211 Interestingly, a few clinical studies also tested DCbased vaccines in combination with ACT and ICBs.…”

Section: Completed Clinical Trialsmentioning

confidence: 99%

See 1 more Smart Citation

Trial watch: Dendritic cell-based anticancer immunotherapy

et al. 2017

View full text Add to dashboard Cite

Dendritic cell (DC)-based vaccines against cancer have been extensively developed over the past two decades. Typically DC-based cancer immunotherapy entails loading patient-derived DCs with an appropriate source of tumor-associated antigens (TAAs) and efficient DC stimulation through a so-called "maturation cocktail" (typically a combination of pro-inflammatory cytokines and Toll-like receptor agonists), followed by DC reintroduction into patients. DC vaccines have been documented to (re)activate tumor-specific T cells in both preclinical and clinical settings. There is considerable clinical interest in combining DC-based anticancer vaccines with T cell-targeting immunotherapies. This reflects the established capacity of DC-based vaccines to generate a pool of TAA-specific effector T cells and facilitate their infiltration into the tumor bed. In this Trial Watch, we survey the latest trends in the preclinical and clinical development of DC-based anticancer therapeutics. We also highlight how the emergence of immune checkpoint blockers and adoptive T-cell transfer-based approaches has modified the clinical niche for DC-based vaccines within the wide cancer immunotherapy landscape.

show abstract

Section: Completed Clinical Trialsmentioning

confidence: 99%

Section: Completed Clinical Trialsmentioning

confidence: 99%

Trial watch: Dendritic cell-based anticancer immunotherapy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Of note, 16 of these studies assessed the safety and efficacy of FDA-approved cytokines (i.e., G-CSF, GM-CSF, IFN-a2a, IFN-a2b and IL-2) as off-label immunostimulatory interventions, [98][99][100][101][102][103][104][105][106][107][108][109][110][111][112][113] while only one trial tested the clinical profile of a hitherto experimental cytokine (i.e., IL-15). 114 The safety and efficacy of G-CSF have been assessed in 11 breast carcinoma patients, who were treated with subcutaneous G-CSF in combination with 5-fluorouracil (5-FU), epirubicin, cyclophosphamide and paclitaxel (NCT02225652).…”

Section: Update On the Development Of Recombinant Cytokines As Immunomentioning

confidence: 99%

“…Finally, subcutaneous low-dose IL-2 has been tested as an adjuvant to autologous DCs in 10 patients with ovarian carcinoma; 102 the safety and efficacy of F16-IL2 (a variant of IL-2 retargeted to the extracellular domain A1 of tenascin C, TNC) 134 administered i.v. in combination with doxorubicinbased chemotherapy have been evaluated first in 10 subjects with advanced solid tumors (to identify a recommended dose) and subsequently in 19 breast carcinoma patients (at the recommended dose); 104 and the clinical profile of recombinant IL-15 given i.v.…”

Section: Update On the Development Of Recombinant Cytokines As Immunomentioning

confidence: 99%

Trial Watch—Immunostimulation with cytokines in cancer therapy

Vacchelli¹,

Aranda

Bloy³

et al. 2015

OncoImmunology

View full text Add to dashboard Cite

During the past decade, great efforts have been dedicated to the development of clinically relevant interventions that would trigger potent (and hence potentially curative) anticancer immune responses. Indeed, developing neoplasms normally establish local and systemic immunosuppressive networks that inhibit tumor-targeting immune effector cells, be them natural or elicited by (immuno)therapy. One possible approach to boost anticancer immunity consists in the (generally systemic) administration of recombinant immunostimulatory cytokines. In a limited number of oncological indications, immunostimulatory cytokines mediate clinical activity as standalone immunotherapeutic interventions. Most often, however, immunostimulatory cytokines are employed as immunological adjuvants, i.e., to unleash the immunogenic potential of other immunotherapeutic agents, like tumor-targeting vaccines and checkpoint blockers. Here, we discuss recent preclinical and clinical advances in the use of some cytokines as immunostimulatory agents in oncological indications.

show abstract

“…The biological function of hemocyanins (Hcs) is to transport oxygen throughout the bodies of some invertebrate animals. Recently, Hcs have been of considerable medicinal interest in cancer immunotherapy due to their high immunogenicity [21,22]. In addition, Tchorbanov et al have achieved enhanced antigen immunogenicity for the epitope of influence A virus hemagglutinin bound to RtH or its subunits and they have suggested that Hcs can be successfully used in many immunization protocols as adjuvants or protein carriers [23].…”

Section: Introductionmentioning

confidence: 99%